TITLE

Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass

AUTHOR(S)
Gruenwald, C.; de Souza, V.; Chan, A.; Andrew, M.
PUB. DATE
June 2000
SOURCE
Perfusion;Jun2000, Vol. 15 Issue 3, p203
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This study was designed to test the validity of whole blood heparin concentration (WHBC) measurements using an on-site protamine titration assay with the Hepcon instrument (Medtronic Blood Management, Parker, CO, USA) in pediatric patients less than 1 year old undergoing cardiopulmonary bypass (CPB). The validity of the Hepcon measurements was examined via a test of correlation with the gold standard plasma antifactor Xa activity (anti-Xa) assay. Fifty-one patients (23 females and 28 males) under 1 year old (mean age 5.3 months) were studied prospectively. Blood samples were taken at 5 min into CPB and at the end of CPB for the WBHC, plasma anti-Xa activity, and hematocrit (Hct). The WBHC was converted to plasma heparin level using a formula taking into account the collection of blood into citrate solution and the effect of the citrate on the hematocrit. While a nonparametric statistical analysis revealed that the mean corrected values from the Hepcon instrument were not significantly different from the mean anti-Xa values (p = 0.070 at 5 min on CPB, p = 0.518 at the end of CPB), there was no significant correlation between these values at either 5 min into CPB (r = 0.113, p = 0.429) or at the end of CPB (r = -0.247, p = 0.080). The lack of correlation between the two assays may be related to the extreme hemodilution observed during CPB in small children, which leads to very low concentrations of coagulation proteins. Due to this discrepancy, whole blood heparin monitors should be further evaluated in children undergoing CPB.
ACCESSION #
3533764

 

Related Articles

  • Editorial. Kurusz, M. // Perfusion;May2008, Vol. 23 Issue 3, p145 

    The article discusses various reports published within the issue, including one by Puri and colleagues on a new monitoring tool for cerebral venous congestion during cardiopulmonary bypass and another by Kordis and colleagues on the benefit of a heparin-coated minimized extracorporeal circuit.

  • Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Flom-Halvorsen, Hanne I; Øvrum, E; Brosstad, F; Tangen, G; Ringdal, MAL; Øystese, R // Perfusion;Sep2002, Vol. 17 Issue 5, p339 

    Objective: The two most commonly used heparin-coated systems for cardiopulmonary bypass (CPB) are the Carmeda Bio-Active Surface (CBAS) (Medtronic, Minneapolis, MN, USA) and the Duraflo II coating (Baxter Healthcare, Irvine, CA, USA). The two surfaces are technically unequal and previous...

  • HEMOSTATIC DEFECTS INDUCED BY CARDIOPULMONARY BYPASS. Bick, Rodger L.; Arbegast, Neil; Crawford, Leah; Holterman, Margaret; Adams, Thompson; Schmalhorst, William // Vascular Surgery;Sep/Oct1975, Vol. 9 Issue 4, p228 

    Discusses studies on a hemorrhagic syndrome associated with a cardiopulmonary bypass (CPB). Causes of the post-CPB hemorrhagic syndrome, including inadequate heparin neutralization; Results of an evaluation of the hemostatic defects induced by CPB; Implications of the presence of fibrinolytic...

  • Massive Intravascular Thrombosis and Thromboembolism after Cardiopulmonary Bypass. Ramsey, Michael A. E.; Marcel, Randy J.; Capeheart, John; Cheung, Edson H.; Ring, W. Steves // Internet Journal of Thoracic & Cardiovascular Surgery;2002, Vol. 5 Issue 2, p83 

    This report describes two patients who underwent cardiac surgery utilizing cardiopulmonary bypass (CPB). Both patients were fully heparinized during the bypass period; however, both of them developed massive intravascular thrombosis and thromboembolism after initiation of heparin reversal with...

  • Intraoperative Anticoagulation Management during Cardiac Transplantation. Wadia, Yasmin; Cooper Jr., John R.; Bracey, Arthur W.; Pinto, Katheleen; Frazier, O. H. // Texas Heart Institute Journal;2008, Vol. 35 Issue 1, p62 

    Heparin-induced thrombocytopenia is an immunologically mediated syndrome that is associated with potentially life-threatening arterial and venous thrombosis. Re-exposing patients who have heparin-induced thrombocytopenia to heparin during cardiopulmonary bypass may be hazardous. We describe the...

  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Wallock, M.; Jeske, W.P.; Bakhos, M.; Walenga, J.M. // Perfusion;Mar2001, Vol. 16 Issue 2, p147 

    Patients undergoing cardiopulmonary bypass (CPB) require anticoagulation with heparin to avoid thrombosis within the bypass circuit. The common method used to monitor the degree of anticoagulation is the activated clotting time (ACT). We evaluated a novel point of care device, the TAS...

  • Centrifugation of salvaged pump blood is useful in reducing the amount of heparin re-infused into the patient. Hoo, A.E.E.; Teng, S.Y.; Chan, T.; James, E.; Ong, B.C. // Perfusion;Jul2001, Vol. 16 Issue 4, p309 

    Conservation of blood and blood products are of major concern in clinical practice today. All blood salvaged from the extracorporeal circuit at the end of cardiopulmonary bypass should be returned to the patient. We propose the use of a simple and inexpensive centrifuge machine to reduce the...

  • Heparin-coated cardiopulmonary bypass circuits: current status. Hsu, L-C. // Perfusion;Sep2001, Vol. 16 Issue 5, p417 

    Heparin-coated circuits have been subjected to vigorous testing, both experimentally and clinically, for the past decade. When the functions of heparin are preserved on the surface, the heparinized surface plays multiple roles in attenuating the systemic inflammatory response. These include the...

  • Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass. von Segesser, L.K.; Mueller, X.; Marty, B.; Horisberger, J.; Corno, A. // Perfusion;Sep2001, Vol. 16 Issue 5, p411 

    Despite the progress made in the development of cardiopulmonary bypass (CPB) equipment, systemic anticoagulation with unfractioned heparin and post-bypass neutralization with protamine are still used in most perfusion procedures. However, there are a number of situations where unfractioned...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics